<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(1)</volume><submitter>Wang C</submitter><pubmed_abstract>The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe drug-resistant infections, caused by Gram-negative bacteria; there is evidence of cefiderocol-resistance occurring in bacterial strains however. To increase the efficacy and extend the life-span of sideromycins, we demonstrate strong synergisms between cefiderocol and metallodrugs (e.g., colloidal bismuth citrate (CBS)), against Pseudomonas aeruginosa and Burkholderia cepacia. Moreover, CBS enhances cefiderocol efficacy against biofilm formation, suppresses the resistance development in P. aeruginosa and resensitizes clinically isolated resi</pubmed_abstract><journal>Nature communications</journal><pagination>5311</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10474269</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance.</pubmed_title><pmcid>PMC10474269</pmcid><pubmed_authors>Xia Y</pubmed_authors><pubmed_authors>Toy PH</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Chan CL</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Kao RY</pubmed_authors><pubmed_authors>Ho PL</pubmed_authors><pubmed_authors>Sun H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance.</name><description>The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe drug-resistant infections, caused by Gram-negative bacteria; there is evidence of cefiderocol-resistance occurring in bacterial strains however. To increase the efficacy and extend the life-span of sideromycins, we demonstrate strong synergisms between cefiderocol and metallodrugs (e.g., colloidal bismuth citrate (CBS)), against Pseudomonas aeruginosa and Burkholderia cepacia. Moreover, CBS enhances cefiderocol efficacy against biofilm formation, suppresses the resistance development in P. aeruginosa and resensitizes clinically isolated resi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2025-05-29T21:44:48.577Z</modification><creation>2025-04-04T11:25:39.894Z</creation></dates><accession>S-EPMC10474269</accession><cross_references><pubmed>37658047</pubmed><doi>10.1038/s41467-023-40828-3</doi></cross_references></HashMap>